Plus Therapeutics, Inc. (PSTV)
0.23
0.00 (0.00%)

0.23
0.00 (0.00%)
Plus Therapeutics, Inc., klinik bosqichdagi farmatsevtika kompaniyasi, saraton kasalligi bilan og'rigan bemorlar uchun davolash usullarini ishlab chiqish, ishlab chiqarish va tijoratlashtirishga qaratilgan. Kompaniyaning yetakchi radioterapiya nomzodi reniy obisbemdadi, bu markaziy asab tizimi va boshqa saraton kasalliklari, jumladan, takroriy glialoblastoma, leptomeningeal metastazlar va bolalar miya saratonlari bilan og'rigan bemorlar uchun patentlangan radioterapiya hisoblanadi. Shuningdek, u intraarterial in'ektsiya orqali birlamchi va ikkilamchi jigar saratoni kabi turli qattiq organ saratonlarini davolash uchun Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere'ni ishlab chiqadi. Bundan tashqari, u karsinomalar va melanomalar bilan og'rigan bemorlarda markaziy asab tizimiga metastazlangan o'simta hujayralarini aniqlash uchun CNSide Testni o'z ichiga olgan laboratoriya tomonidan ishlab chiqilgan testlarni ishlab chiqadi va tijoratlashtiradi. Kompaniya ilgari Cytori Therapeutics, Inc. nomi bilan tanilgan va 2019 yil iyul oyida Plus Therapeutics, Inc. nomini o'zgartirgan. Plus Therapeutics, Inc. 1996 yilda tashkil etilgan va shtab-kvartirasi Xyuston, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Marc H. Hedrick M.B.A., M.D. | President, CEO & Director |
| Mr. Andrew J. Sims CPA | VP & CFO |
| Mr. Russ Havranek M.B.A., M.S. | Executive Vice President of Commercial and Corporate Strategy |
| Mr. Russell W. Bradley | President & GM of CNSide Diagnostics, LLC |
| Ms. Desiree Smith | Corporate Controller |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-12 | 8-K | pstv-20260312.htm |
| 2026-01-22 | 8-K | d90055d8k.htm |
| 2026-01-16 | 8-K | d65677d8k.htm |
| 2026-01-13 | S-1MEF | d137302ds1mef.htm |
| 2026-01-09 | S-1 | d12907ds1.htm |
| 2025-11-25 | DRS | filename1.htm |
| 2025-11-17 | 8-K | d55484d8k.htm |
| 2025-10-30 | 10-Q | pstv-20250930.htm |
| 2025-10-21 | 8-K | d637082d8k.htm |
| 2025-08-26 | 8-K | d919644d8k.htm |